A late-stage drug development company specific in oncology and endocrinology.

, a late-stage drug development company specific in oncology and endocrinology, today announced that it’ll make an oral display, as well as a poster display on Erk/PI3K inhibitor compounds, Tuesday, April 20, at the American Association for Cancer tumor Analysis Annual Meeting, april 17-21 to become kept, 2010 at the Walter E. Washington Convention Center in Washington, D suhagra.org .C. Abstract # 3856 – Title: ‘A highly selective Erk-inhibitor with antiproliferative efficacy and the potential for combination therapy with modulators of the PI3K pathway’, I.